HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio, company leadership, and institutional investors.
The proceeds will be used to fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities, and for general corporate purposes. This funding is critical as the company seeks to bring its innovative cardiac monitoring solutions to market.
HeartBeam is developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence to physicians. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to its technology.
The successful closing of this offering underscores investor confidence in HeartBeam’s approach to transforming cardiac care. By enabling remote monitoring and early detection of heart conditions, the company aims to reduce the burden on healthcare facilities and improve patient outcomes. The funds will accelerate the rollout of its products, potentially expanding access to advanced cardiac diagnostics beyond traditional clinical settings.
For more details, visit the full press release at https://ibn.fm/9iNYY. Updates on the company are available in its newsroom at https://ibn.fm/BEAT.
This announcement is important as it positions HeartBeam to commercialize technologies that could significantly impact the detection and monitoring of cardiac conditions, potentially saving lives through earlier intervention. The funding also supports the expansion of AI capabilities, which could enhance diagnostic accuracy and efficiency.
